SOURCE: BioCentury Publications

BioCentury Publications

January 11, 2010 07:30 ET

BioCentury Publishes Investor Picks for New Biotech Bellwethers in 2010

SAN FRANCISCO, CA--(Marketwire - January 11, 2010) - Biopharmaceutical investors gathering here this week for the 28th Annual J.P. Morgan Healthcare Conference anticipate that four potential blockbusters could be produced by biotechnology companies this year, and propel the ascendance of a new class of bellwethers in the sector.

Asset managers polled in the 18th Annual Buyside View, published today in BioCentury, the Bernstein Report on BioBusiness, also see value in big cap biotech names, which are seen as ripe for an upward move after losing their luster compared to big pharma in 2009.

With biotech companies raising $6 billion from follow-ons in 2009 -- the second-largest follow-on year on record -- investors expect even a mild economic recovery will bode well for public biotechs in 2010, providing enough stability to allow smaller cap companies to access cash.

Specialist investors also anticipate increasing interest from generalist fund managers who have been underweight in healthcare, putting momentum behind big pharma and big cap biotech names.

"There's room for the biotech group to move up without overheating," said Karen Bernstein, Ph.D., Chairman & Editor-in-Chief of BioCentury. "While the broader healthcare indices outpaced the general markets in 4Q09, the biotech space has yet to follow suit."

According to the Buyside View and BioCentury's companion 2010 Financial Markets Preview, the compounds to watch this year include Prolia denosumab for osteoporosis from Amgen Inc. (NASDAQ:AMGN), along with three drugs that could elevate their developers into biotech's top tier: Benlysta belimumab for lupus from Human Genome Sciences Inc. (NASDAQ:HGSI), telaprevir for hepatitis C from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and Provenge sipuleucel-T for prostate cancer from Dendreon Corp. (NASDAQ:DNDN).

Investors also are seeing a full calendar of late-stage clinical and regulatory milestones in diseases ranging from Alzheimer's and cancer to cystic fibrosis, diabetes and heart failure, including companies such as:

Acorda Therapeutics Inc. (NASDAQ:ACOR)
Affymax Inc. (NASDAQ:AFFY)
Allos Therapeutics Inc. (NASDAQ:ALTH)
Amylin Pharmaceuticals Inc. (NASDAQ:AMLN)
Elan Corp. plc (NYSE:ELN)
Genmab A/S (CSE:GEN)
Gilead Sciences Inc. (NASDAQ:GILD)
Labopharm Inc. (TSX:DDS; NASDAQ:DDSS)
MannKind Corp. (NASDAQ:MNKD)
Medivation Inc. (NASDAQ:MDVN) 
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA)
Pharmaxis Ltd. (ASX:PXS)
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)
Shire plc (LSE:SHP; NYSE:SHPGY)
Wilex AG (Xetra:WL6)

Products from these companies are included in BioCentury's lists of more than 125 late-stage clinical milestones upcoming for biotech and pharma companies in 2010, along with anticipated FDA or EMEA actions on nearly 40 drug applications.

To get the full roster of industry milestones and the buysider picks, download a free PDF copy of the 18th Annual Buyside View and the 2010 Financial Markets Preview.

BioCentury kicks off each year with the Buyside View and the BioCentury Financial Markets Preview. This agenda-setting package surveys senior venture capital investors, global money managers and investment bankers to identify the drivers for investment in biotech drug and diagnostics developers for the coming year.

The predictions of these thought leaders are supported by key benchmarks of industry financial performance and newsworthy company and product milestones compiled using BioCentury's BCIQ™ online business intelligence platform.

The first Buyside View was published in 1993 in conjunction with the Hambrecht & Quist Life Science Conference, the precursor to this week's J.P. Morgan event. With the 2010 report, BioCentury is beginning its 18th year as the gatekeeper for market intelligence for the biotechnology industry and its partners in the investment community and the pharmaceutical industry.

January also begins the third year of SciBX: Science-Business eXchange™, BioCentury's joint publishing venture with Nature Publishing Group. SciBX provides the first comprehensive compendium of scientific developments with commercial potential in the biopharma industries. To find out more, go to www.scibx.com.

To start a trial of BioCentury, the Bernstein Report on BioBusiness, please email subscribe@biocentury.com, or call +1 650-595-5333.

To start a trial of SciBX, please email SciBX@biocentury.com.

To request a trial of BCIQ, please email BCIQ@biocentury.com.

Upcoming BioCentury Financial Conferences

The 17th Annual Future Leaders in the Biotech Industry
April 8, 2010, New York City

The 11th Annual BioEquity Europe 2010
May 19-20, 2010
Zurich, Switzerland

The 17th Annual NewsMakers in the Biotech Industry
Fall 2010, New York City

Click below for registration and more details on each: http://biocentury.com/BCApp/BioCenturyCommon/BCConferences.aspx?ss=1

About BioCentury™

BioCentury Publications, Inc., independently owned and based in Redwood City, Calif., provides essential biopharma intelligence from offices in the U.S. and Europe. For more than 17 years, a global audience of biotech and pharmaceutical executives and investors has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, online business intelligence resources and collaborative industry conferences. Long respected for the thought leadership provided by BioCentury, the Bernstein Report on BioBusiness™, the company also publishes BioCentury Extra, a concise daily news report for executives, and BioCentury Part II, a complete weekly compendium of deals, product developments and financing events. SciBX: Science-Business eXchange™, BioCentury's joint publishing venture with Nature Publishing Group, provides the first comprehensive compendium of new scientific developments with commercial potential for the biotechnology and pharmaceutical industries. These authoritative reports are backed by the BCIQ™ online business intelligence platform, which provides access to information on more than 5,000 public and private companies, 10,000 biopharma compounds and $260 billion in financings. For more information, please visit www.biocentury.com.

BioCentury™; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™, Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™ are trademarks of BIOCENTURY PUBLICATIONS, INC. Copyright © 2010. ALL RIGHTS RESERVED. SciBX and SciBX: Science-Business eXchange are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.

Contact Information

  • Media Inquiries Contact:
    Thomas C. Carey
    Vice President of Commercial Operations
    BioCentury Publications, Inc.
    +1 650 595-5333
    tcarey@biocentury.com